The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Abstract
BACKGROUND We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk inadequately controlled on oral glucose-lowering medications. METHODS This open-label, parallel-group, phase 3 study was done in 187 sites in 14 countries on five continents. Eligible participants, aged 18 years or older, had type 2 diabetes treated with any combination of metformin, sulfonylurea, or sodium-glucose co-transporter-2 inhibitor, a baseline glycated haemoglobin (HbA1c) of 7·5-10·5% (58-91 mmol/mol), body-mass index of 25 kg/m2 or greater, and established cardiovascular disease or a high risk of cardiovascular events. Participants were randomly assigned (1:1:1:3) via an interactive web-response system to subcutaneous injection of either once-per-week tirzepatide (5 mg, 10 mg, or 15 mg) or glargine (100 U/mL), titrated to reach fasting blood glucose of less than 100 mg/dL. The primary endpoint was non-inferiority (0·3% non-inferiority boundary) of tirzepatide 10 mg or 15 mg, or both, versus glargine in HbA1c change from baseline to 52 weeks. All participants were treated for at least 52 weeks, with treatment continued for a maximum of 104 weeks or until study completion to collect and adjudicate major adverse cardiovascular events (MACE). Safety measures were assessed over the full study period. This study was registered with ClinicalTrials.gov, NCT03730662. FINDINGS Patients were recruited between Nov 20, 2018, and Dec 30, 2019. 3045 participants were screened, with 2002 participants randomly assigned to tirzepatide or glargine. 1995 received at least one dose of tirzepatide 5 mg (n=329, 17%), 10 mg (n=328, 16%), or 15 mg (n=338, 17%), or glargine (n=1000, 50%), and were included in the modified intention-to-treat population. At 52 weeks, mean HbA1c changes with tirzepatide were -2·43% (SD 0·05) with 10 mg and -2·58% (0·05) with 15 mg, versus -1·44% (0·03) with glargine. The estimated treatment difference versus glargine was -0·99% (multiplicity adjusted 97·5% CI -1·13 to -0·86) for tirzepatide 10 mg and -1·14% (-1·28 to -1·00) for 15 mg, and the non-inferiority margin of 0·3% was met for both doses. Nausea (12-23%), diarrhoea (13-22%), decreased appetite (9-11%), and vomiting (5-9%) were more frequent with tirzepatide than glargine (nausea 2%, diarrhoea 4%, decreased appetite <1%, and vomiting 2%, respectively); most cases were mild to moderate and occurred during the dose-escalation phase. The percentage of participants with hypoglycaemia (glucose <54 mg/dL or severe) was lower with tirzepatide (6-9%) versus glargine (19%), particularly in participants not on sulfonylureas (tirzepatide 1-3% vs glargine 16%). Adjudicated MACE-4 events (cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina) occurred in 109 participants and were not increased on tirzepatide compared with glargine (hazard ratio 0·74, 95% CI 0·51-1·08). 60 deaths (n=25 [3%] tirzepatide; n=35 [4%] glargine) occurred during the study. INTERPRETATION In people with type 2 diabetes and elevated cardiovascular risk, tirzepatide, compared with glargine, demonstrated greater and clinically meaningful HbA1c reduction with a lower incidence of hypoglycaemia at week 52. Tirzepatide treatment was not associated with excess cardiovascular risk. FUNDING Eli Lilly and Company.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In comparison, placebo-corrected weight loss induced by tirzepatide or semaglutide, at this treatment time point in a comparable study population, was ~17%142, and ~13%165, respectively.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [165]
In the citing paper
“In the Phase III clinical trial program, tirzepatide demonstrated superior glycemic ef fi cacy to placebo (183,184), subcutaneous semaglutide 1.0 mg weekly (185), insulin degludec (186), and insulin glargine (187).”
In the citing paper
“In the SURPASS trials, tirzepatide consistently outperformed placebo and active comparators in reducing HbA1c across all doses [90, 93–96].”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [94]
In the citing paper
“The health benefits seen with continued treatment with the maximum tolerated dose of tirzepatide during this study were achieved with a safety profile consistent with that previously reported in SURMOUNT and SURPASS trials and in studies of incretin-based therapies approved for the treatment of obesity and overweight.18,25,26,27,28,29,30,31,32”
From Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (2024) · cites this paper as [28]
In the citing paper
“Tirzepatide is a novel, once-weekly dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist that is administered via subcutaneous injection and has shown statistically significant reductions in hemoglobin A 1c (HbA 1c ) and body weight compared with the GLP-1 receptor agonist semaglutide (1 mg), 11 insulin degludec, 12 and insulin glargine 13 when added to oral glucose-lower”
From Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (2022) · cites this paper as [13]
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Self-citationMultiple Imputation for Nonresponse in Surveys.
Lynn, P., & Rubin, D. B. (1988) · The Statistician · doi:10.2307/2348774 · Cited by 2,329
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citation
Cited by
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationAhmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Self-citationGlucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“139 – 141 Although dual agonists show advantages in ef fi cacy, their safety and tolerability continue to be a focus of ongoing monitoring.”
Background
Metadata
- Authors
- Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., Wiese, R. J., Ahmann, A. J., Arora, S., Ball, E. M., Calderon, R. B., Butuk, D. J., Chaychi, L., Chen, M. C., Curtis, B. M., Chochinov, R., Chow, C., Cone, C. L., Connery, L., Cortes-Maisonet, G. A., de Souza, J., Dungan, K., Bradley, D., Frias, J. P., Gabra, N., Gaudiani, L., Herandez-Vazquez, L., Hsia, S. H., Jardula, M. R., Klein, E. J., Kutner, M. E., Loy, J., Miranda, F. G., Nunez, L. D., Mujica-Baella, M., Murray, A. V., Oliver, M. J., Oritz-Carrasquillo, R., Palal, B., Parke, M. T., Philis-Tsimikas, A., Purighalla, R. S., Rosenstock, J., Sathananthan, A., Shelton, C., Sivalingam, K., Sorial, E., Soufer, J., Stacey, H. L., Stonesifer, L. D., Stringam, S., Van, J. T., Vazquez-Tanus, J. B., Reyes, R., Welch, M., Karimjee, N., Martin, E. E., Arif, A., Jennings, T. W., Fraser, N. J., Bhargava, A., Wynne, A. G., Davidson, E., Billings, L., Barranco-Santana, E. A., Dever, M. E., Walsh, P., Cho, A., Chu, J. W., Shubrook, J., Knouse, A. B., Nadar, V., Lewy-Alterbaum, L., Lillestol, M. J., Humiston, D. J., White, A. J., Mayfield, R. K., Bitar, F. G., Cereto, F., de la Cuesta, C., De Teresa Parreno, L., Jodar Gimeno, E., Mezquita-Raya, P., Morales Portillo, C. J., Quesada Charneco, M., Tinahones Madueno, F. J., Tofe Povedano, S., Vazquez, L., Fajardo Montañana, C., Soto Gonzalez, A., Mistodie, C., Szilagyi, I., Filimon, A., Mindrescu, N. M., Pop, L., Pascu, M., Negrisanu, G. D., Ciomos, D., Neacsu, V., Thury-Burileanu, A., Liberty, I., Stern, N., Sofer, Y., Sack, J., Shimon, I., Tirosh, A., Ishay, A., Mosenzon Ninio, O., Shehadeh, N., Wainstein, J., Darawsha, M., Skripova, D., Pavleova, E., Donicova, V., Kubincova, L., Sosovec, D., Merciakova, M., El Boreky, F., St-Amour, E., Yared, Z., Blouin, F., Ajala, B., Aggarwal, N. K., Bajaj, H., Tailor, C., Egan, A., O'Mahony, J., St.Onge, N., Conway, J. R., Akerman Augusto, G., Borges, J. L. C., Gomes Cerqueira, M. J. A., Franco, D. R., Franco Hirakawa, T., Souza, F. D., Hissa, M. N., Pechmann, L. M., Calil Salim, C. P., Russo, L. A. T., Siqueira, J., Sassone, S. A., Glenny, J. A., Koretzky, M., Aizenberg, D., Steinacher, A., Solis, S. E., Nardone, L., Perez Manghi, F. C., Orio, S. I., Gelersztein, E., Fretes, J. O., Calella, P. R. F., Zaidman, C. J., Chertkoff, A., Salzberg, S., Majul, C. R., Nevarez, L. A., Violante Ortiz, R. M., Banda Elizondo, R. G., Arjona Villicaña, R. D., Gonzalez Galvez, G., Calvo, C. G., Koscianski, A., Rudzki, H., Stankiewicz, A. W., Sowinski, D., Krzyzagorska, E., Jozefowska, M., Matyjaszek-Matuszek, B., Franek, E., Skokowska, E., Modzelewska, A., Szyprowska, E., Simpson, R. W., Gilfillan, C., Colquhoun, D. M., Davis, T. M., Morbey, C., McCarthy, S. E., Kaur, K., Kemp, L., Shea, A. J., Khalimov, Y. S., Miroshnichenko, O. A., Dvoryashina, I. V., Karpova, I. A., Kunitsyna, M. A., Vorokhobina, N. V., Galstyan, G. R., Bondar, I. A., Filippov, E. V., Ershova, O. B., Ou, H.-Y., Tseng, S.-T., Chen, J.-F., Tien, K.-J., Huang, C.-N., Chen, C.-C., Hwu, C.-M., Hsia, T.-L., Doupis, J., Pagkalos, E., Mouslech, Z., Bargiota, A., & Kotsa, K.
- Affiliations
- University of Washington (US)
- Eli Lilly (United States) (US)
- ORCID
- Kahn, Steven E
- Pavo, Imre
- Weerakkody, Govinda J
- Yang, Zhengyu
- Riesmeyer, Jeffrey S
- Wiese, Russell J
- Ahmann, Andrew J
- Chen, Michael C
- Dungan, Kathleen
- Bradley, David
- Hsia, Stanley H
- Rosenstock, Julio
- Sorial, Ehab
- Stacey, Helen L
- Van, Joanna T
- Bhargava, Anuj
- Billings, Liana
- Shubrook, Jay
- Pop, Lavinia
- Liberty, Idit
- Stern, Naftali
- Sofer, Yael
- Sack, Jessica
- Shimon, Ilan
- Tirosh, Amir
- Ishay, Avraham
- Shehadeh, Naim
- Wainstein, Julio
- Aggarwal, Naresh K
- Bajaj, Harpreet
- Franco, Denise R
- Souza, Filipe D
- Pechmann, Luciana M
- Salzberg, Susana
- Franek, Edward
- Gilfillan, Christopher
- Davis, Timothy M
- McCarthy, Shannon E
- Dvoryashina, Irina V
- Karpova, Irina A
- Galstyan, Gagik R
- Ershova, Olga B
- Ou, Horng-Yih
- Tseng, Shih-Ting
- Chen, Jung-Fu
- Tien, Kai-Jen
- Huang, Chien-Ning
- Chen, Ching-Chu
- Hwu, Chii-Min
- Kotsa, Kalliopi
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 398
- Issue
- 10313
- Pages
- 1811-1824
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3205201678
- Semantic Scholar
- cba69af6775b7c366525afc319d539f9dc04fc83
- Cited by
- 684
- References
- 36
- Citations by year
- 2026: 118 · 2025: 155 · 2024: 166 · 2023: 151 · 2022: 88 · 2021: 6
- FWCI
- 76.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- AstraZeneca
- Sanofi
- Eli Lilly and Company
- Novartis Pharmaceuticals Corporation
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tirzepatide, insulin glargine, type 2 diabetes, cardiovascular risk, major adverse cardiovascular events, HbA1c, GIP/GLP-1 receptor agonist, non-inferiority, glycemic control, cardiovascular safety, metformin, SGLT2 inhibitors
- MeSH terms
- Insulin Glargine, Tirzepatide, Adult, Aged, Blood Glucose, Body Weight, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)02188-7
- The paper
- Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., Wiese, R. J., Ahmann, A. J., Arora, S., Ball, E. M., Calderon, R. B., Butuk, D. J., Chaychi, L., Chen, M. C., Curtis, B. M., . . . Kotsa, K. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)02188-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.